prikaz prve stranice dokumenta Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia
  Preuzmi
PDF 852.89 KB
Znanstveni rad - Izvorni znanstveni rad
Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia
Leukemia & Lymphoma, 61 (2020), 4; 934-939. https://doi.org/10.1080/10428194.2019.1702182
Pejša, Vlatko; Lucijanić, Marko; Vrkljan Vuk, Anamarija; Štoos-Veić, Tajana; Jakšić, Ozren; Jonjić, Željko; Piršić, Mario; Prka, Željko; Ivić, Marija; Fazlić Džankić, Amina; Mitrović, Zdravko

Citirajte ovaj rad

Pejša, V., Lucijanić, M., Vrkljan Vuk, A., Štoos Veić, T., Jakšić, O., Jonjić, Ž. ... Mitrović, Z. (2020). Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma, 61. (4), 934-939. doi: 10.1080/10428194.2019.1702182

Pejša, Vlatko, et al. "Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia." Leukemia & Lymphoma, vol. 61, br. 4, 2020, str. 934-939. https://doi.org/10.1080/10428194.2019.1702182

Pejša, Vlatko, Marko Lucijanić, Anamarija Vrkljan Vuk, Tajana Štoos Veić, Ozren Jakšić, Željko Jonjić, Mario Piršić, et al. "Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia." Leukemia & Lymphoma 61, br. 4 (2020): 934-939. https://doi.org/10.1080/10428194.2019.1702182

Pejša, V., et al. (2020) 'Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia', Leukemia & Lymphoma, 61(4), str. 934-939. doi: 10.1080/10428194.2019.1702182

Pejša V, Lucijanić M, Vrkljan Vuk A, Štoos Veić T, Jakšić O, Jonjić Ž, i sur.. Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma [Internet]. 04.2020. [pristupljeno 07.10.2024.];61(4):934-939. doi: 10.1080/10428194.2019.1702182

V. Pejša, et al., "Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia", Leukemia & Lymphoma, vol. 61, br. 4, str. 934-939, Travanj 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:272145. [Citirano: 07.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:272145
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia
AutorVlatko Pejša
AutorMarko Lucijanić
AutorAnamarija Vrkljan Vuk
AutorTajana Štoos-Veić
AutorOzren Jakšić
AutorŽeljko Jonjić
AutorMario Piršić
AutorŽeljko Prka
AutorMarija Ivić
AutorAmina Fazlić Džankić
AutorZdravko Mitrović
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
First obinutuzumab application is associated with infusion related reactions (IRRs) that may discourage further continuation of the drug. During our clinical practice we have observed that chronic lymphocytic leukemia (CLL) patients with autoimmune hemolytic anemia (AIHA) prolongedly receiving corticosteroids do not develop obinutuzumab IRRs. Therefore, we decided to apply prolonged corticosteroid premedication with methylprednisolone in dose 1-1.5 mg/kg for ≥7 days to all further obinutuzumab candidates. Here we present non-randomized comparison of 28 consecutive previously untreated CLL patients receiving prolonged corticosteroid premedication (15 patients) or standard premedication (13 patients) prior to the first obinutuzumab infusion. Prolonged corticosteroid premedication resulted in significant reduction of all-grade (20% vs 61.5%; p = .025) and grade III (0% vs 23.1%; p = .049) obinutuzumab IRRs. Prolonged corticosteroid premedication did not significantly affect occurrence of infective complications. Patients with CLL and AIHA receiving obinutuzumab showed continuous and stable increase in hemoglobin levels concomitantly with decrease in parameters of hemolysis.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaLeukemia & Lymphoma
Brojčani podacivol. 61, br. 4, str. 934-939
p-ISSN1042-8194
e-ISSN1029-2403
DOIhttps://doi.org/10.1080/10428194.2019.1702182
URN:NBNurn:nbn:hr:105:272145
Datum objave publikacije2020-04
URL dokumentahttps://www.tandfonline.com/doi/full/10.1080/10428194.2019.1702182
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Datum isteka embarga: 2021-04-30
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2020-12-10 09:22:37